Normalized claim
Cost: 75% decrease
AI adoption reported to reduce costs and boost customer satisfaction (confirmed by 75% CXOs).
Last evidence check: Jul 22, 2026
EY-Parthenon and Microsoft boost AI adoption in Pharma
Use case typeDrug discoveryUpdated Jun 13, 2026
The joint EY-Parthenon and Microsoft report highlights AI’s transformational potential in the pharmaceutical sector and provides a comprehensive AI Maturity Framework to support widespread AI adoption. Reporting at BioAsia 2025, it reveals the steady integration of AI for drug discovery, manufacturing efficiencies, and patient-centered advancements. Featured challenges include algorithm bias, data security, workforce readiness, and regulatory hurdles, which are pivoted into opportunities for strategic growth. Innovations such as AI-optimized clinical trials and compliance automation were showcased, emphasizing the tool's potential to reshape life sciences operations.
Why do we believe this?Outcome claims, sources, and evidence checks
Why do we believe this deployment?Customer identity, provider attribution, maturity, and source checks
- Customer
- None
- Provider
- Microsoft
- Maturity
- Production
- Linked source
- EY
Enhanced operational efficiencies in manufacturing/supply chains
Customer identity supportedSource describes one deploymentMaturity supported
Primary read
Use case focus
Showing 3 of 3
- 1compliance automation
- 2clinical trial optimization
- 3predictive maintenance in medical devices
- Developed AI-powered tools for regulatory compliance automation.
- Implemented AI processes to optimize clinical trials and patient recruitment.
- Promoted AI for accelerating drug discovery processes and R&D.
- Introduced a structured roadmap for scaling AI enterprise-wide via Microsoft and EY.
- Leveraged predictive maintenance and medical device modeling in MedTech.
- Improved trial planning and patient-centered healthcare methods.
- Accelerated drug discovery, reducing time to market.
- Enhanced operational efficiencies in manufacturing/supply chains.
Architecture
EY-Parthenon and Microsoft’s framework categorizes organizations into AI Maturity levels and identifies their integration points: foundational, innovative, transformational. AI enables pharmaceutical R&D modeling, toxicity assessment, regulatory compliance. Optimized broader supply chain and MedTech innovation involve AI-first technical recalibrations.
Sources & evidence2
Evidence: Low30/100Evidence strength
- Quantified outcome available
- Multiple corroborating sources available
- Recent evidence check available
- Last evidence check: Jul 22, 2026.
Live sourceStill referenced
The case's original source is still reachable.
- Cited source last checked Jun 12, 2026 — ok (0/2 broken).
Measures whether this deployment's public evidence persists — not whether the system is still in production.
Type: Press ReleasePublished: Apr 1, 2025Publisher: EYEvidence: VendorConfidence: Medium
AI-generated summary. Verify important details with the linked sources before relying on this case.
Explore related AI use cases
Customer evidence
Provider evidence
Browse the catalog
Was this useful?
Community
Comments
No published comments yet.